S100A8 and myeloproliferative neoplasm: Our work, through RNA-Seq, followed by in vitro and clinical validations, provides an innovative perspective on how S100A8 may be differentially activated in type 1 CALR-mutated MPN, a finding that could offer potential implications for therapeutic and prognostic purposes.